SCHEMBL25529311

SCHEMBL25529311

CCC(C)(C)C(=O)NNC(=O)c1ccccc1Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 9/20 0.48
ABCG2 Q9UNQ0 1/20 0.43
TAS2R14 Q9NYV8 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
MAPK8 P45983 1/20 0.43
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
YAP1 P46937 1/20 0.42
TEAD4 Q15561 1/20 0.42
TEAD2 Q15562 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PTGS1 P23219 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
NR1H4 Q96RI1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22556311 0.91 RXFP1 (0.48) RXFP1ABCG2TAS2R14AKR1C3AKR1C2
SCHEMBL22556374 0.90 RXFP1 (0.47) RXFP1ABCG2TAS2R14AKR1C3AKR1C2
SCHEMBL22556341 0.87 RXFP1 (0.51) RXFP1ABCG2TAS2R14AKR1C3AKR1C2
SCHEMBL22556328 0.85 RXFP1 (0.46) RXFP1ABCG2TAS2R14AKR1C3AKR1C2
SCHEMBL23112794 0.85 RXFP1 (0.52) RXFP1ABCG2TAS2R14AKR1C3AKR1C2
SCHEMBL22571350 0.84 RXFP1 (0.51) RXFP1ABCG2TAS2R14AKR1C3AKR1C2
SCHEMBL22556330 0.84 RXFP1 (0.43) RXFP1ABCG2TAS2R14AKR1C3AKR1C2
SCHEMBL22556361 0.84 NPSR1 (0.50) RXFP1ABCG2TAS2R14HTTNPSR1
SCHEMBL22556315 0.83 RXFP1 (0.47) RXFP1ABCG2TAS2R14AKR1C3AKR1C2
SCHEMBL22571456 0.83 RXFP1 (0.47) RXFP1ABCG2TAS2R14AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11661403-B2 Oxadiazole compounds YAP1, TEAD2, TEAD3 RXFP1 3511/4885ABCG2 2985/4885TAS2R14 4508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.